Introduction
Type 2 Diabetes Mellitus (T2DM) is considered one of the major metabolic diseases of 21st century. The excessive food intake, sedentary life style, and lack of physical activity are responsible for the growing epidemic of obesity, together with the increasing rate of T2DM in many parts of the world. Type 2 Diabetes Mellitus arises from two defects: impaired insulin action and impaired β-cell function/insulin secretion of pancreas. Impaired insulin action (i.e., insulin resistance) occurs when target tissues are unable to respond to normal circulating concentrations of insulin. The incidence of obesity has dramatically increased, and become epidemic in the western world. Obesity is a major risk factor for the development of several chronic diseases including T2DM. Obesity characterized by increased storage of fatty acids has an expanded adipose tissue mass and closely associated with the development of insulin resistance in peripheral tissues as skeletal muscle and the liver. Both obesity and T2DM are causally linked through their association with the development of insulin resistance. Adipose tissue is a complex, essential, and highly active metabolic and endocrine organ. The classical perception of adipose tissue as a storage place of fatty acids has been replaced over the last years by the notion that adipose tissue has a central role in lipid and glucose metabolism and produces a large number of hormones and cytokines. These chemical messengers, collectively known as "adipocytokines or adipokines," include tumour necrosis factor alpha (TNF-α), adiponectin, leptin, resistin and visfatin [1] . Various signalling molecules secreted by adipocytes have been implicated in the development of insulin resistance and T2DM, based on results from animal models and metabolic studies in humans [2] . Adiponectin is the most abundantly expressed adipokine and differs from the other adipocytokines in that its concentrations decrease with increasing obesity and increase with weight loss [3] . Amount of adiponectin released increased with fat cell size and the levels of adiponectin decreased when BMI increased [4] . Adiponectin has been suggested to have insulin sensitizing, anti-inflammatory and anti-atherogenic effects [5, 6] . The strength and consistency of the relation between plasma adiponectin and risk of T2DM is unclear [7] . Visfatin, a new adipokine, was described recently and facilitates adipogenesis and has insulin-mimetic properties and reduces plasma glucose levels [8] . Visfatin is expressed in many cells and tissues and was previously identified as a protein involved in B-cell maturation (pre-B-cell colony-enhancing factor). Several clinical studies were conducted in order to analyse the validity of visfatin data and its relationship with insulin resistance, diabetes and obesity. However, there are controversies in the results of these studies [9, 10] . Other investigators have also found increased levels of visfatin in type 2 diabetic patients but failed to find a correlation between anthropometric measurements, lipid measures, fasting glucose, insulin resistance [11] . Therefore there are a number of disagreements among the different studies about visfatin and the role of this adipocytokines in obesity and insulin resistance is not clear. We aimed to investigate the roles of adiponectin and visfatin levels on insulin resistance and obesity in Type 2 Diabetes Mellitus. Patients and controls were non-smokers. None of the individuals included in the study were using alcohol or taking vitamin supplements, other antioxidants and hormone replacement therapy.
Materials and Methods

Study population
All individuals in both patient and control group were informed about the study and their signed approvals were obtained. The some patients with T2DM were using ACE (Angiotensin-converting-enzyme) inhibitors (n=10), statins (n=8) and oral antidiabetic agents (n=45), but anybody was not applied insulin therapy.
Blood sample collection
In order to prevent interference, individual patients and controls were advised not to do heavy exercise, drink or smoke and eat anything prior to blood sampling. Venous blood samples were collected from an antecubital vein (7.00-9.00 a.m.) after a 12-h overnight fasting period, 10 ml of venous blood from each patients were sampled to biochemistry tubes with gel separator and to heparinised tubes for HbA1C (Haemoglobin A1C) measurements. Biochemistry tubes were centrifuged at 2000xg for 15 min after an incubation period of 30 min. Fasting glucose and HbA1C measurements were performed in the same day when serum were separated from blood samples. Remaining serum specimens were kept at -20°C until adiponectin and visfatin analyses were performed.
Biochemical analyses
Glucose levels were measured in a MODULER analyser using Roche Diagnostic kits by enzymatic colorimetric method. Insulin levels were measured by chemiluminescence method using IMMULITE-I analyser with DPC (Diagnostic Products Corporation Los Angeles, CA USA) kits. HbA1C levels were measured by turbidimetry immunoassay method using Hitachi 917 analyser with Roche Diagnostic kits. Serum adiponectin levels were measured by Enzyme Linked Immunosorbent Assay (ELISA) using AviBion Human Adiponectin (Orgenium Laboratories, Helsinki) ELISA test kits. Adiponectin test was evaluated by intraassay precision (≤10%, CV %) and inter-assay precision (<12%, CV %) according to the given information by kit manufacturer. Serum visfatin levels were measured by Enzyme Linked Immunosorbent Assay (ELISA) using Biosource Immunoassay test (Biosource International, Inc., USA) Human Visfatin ELISA test kits. Visfatin test was evaluated by intra-assay precision (7.76%, CV %) and inter-assay precision (7.97%, CV %) according to the given information by kit manufacturer. These sums did not repeat in our laboratory.
Calculation
Body mass index (BMI) was calculated by dividing the weight value of the patient to the square of height value. The estimate of insulin resistance by HOMA (homeostatic model assessment) score was calculated with the formula: fasting serum insulin (μU/ml) x fasting plasma glucose (mmol/l)/22.5. With such a method, high HOMA scores denote low insulin sensitivity (insulin resistance). Patients with T2DM were divided two subgroups according to current WHO classification of [12] 
Results
Clinical and biochemical features of patients and controls were presented in Table 1 . Table 1 summarized the clinical and biochemical characteristics of controls and T2DM patients. Considering age, when nonobese and obese T2DM and controls are comparised, no difference was observed. However HOMA-IR (p<0.001), HbA1C (p<0.001), glucose (p<0.001) in both obese and nonobese T2DM groups were significantly higher than controls. BMI levels were increased in obese group compared with nonobese (p<0.001) and control (p<0.001) group. The results of visfatin and adiponectin are shown in Figure 1 and 2 , respectively. Serum adiponectin levels of nonobese and obese T2DM were decreased as compared to that in control group (p<0.01 and p<0.001; respectively). Moreover adiponectin levels of obese diabetic patients were also lower than that nonobese but not significant for statistical (p>0.05). Serum visfatin levels of obese T2DM patients were increased as compared to that in controls (p<0.001) but visfatin levels of controls and nonobese T2DM patients, obese and non -obese T2DM patients was not different (p>0.05). Table 2 represents the relationship between serum adiponectin and visfatin levels with age, glucose, DM duration, HOMA-IR, BMI in all T2DM groups (n=45). Serum adiponectin levels were negatively correlated with BMI, glucose, HOMA-IR, HbA1C whereas visfatin was only positively correlated with BMI and HOMA-IR.
Conclusion
In the present study, we measured total serum adiponectin and visfatin levels in T2DM patients that were divided into by BMI levels to investigate their relationship with obese and non-obese diabetics. There are unclear data concerning the role of these adipokines. As a consequence of sustained over nourishment, obesity has become epidemic in worldwide. Obesity, especially visceral obesity, which is the accumulation of adipose tissue inside the abdominal cavity, is associated with resistance to the effects of insulin [IR (insulin resistance)], often leading to the development of T2DM. Type 2 Diabetes Mellitus is an important health problem since the incidence of T2DM is continuously increasing [13] . Although adipose tissue was regarded only stores energy until the last decade, it is now known as the largest endocrine organ of the body. Adipose tissue is an active tissue that secretes multiple metabolically important proteins called 'adipokines'. Several studies have shown that the production of some adipokines such as adiponectin and visfatin is influenced in obesity and in type 2 diabetes. Adiponectin is a 30-kDa protein that highly expressed in adipose tissue but a lot of studies show that its levels paradoxically decreased in obesity. In obese animals, treatment with adiponectin decreases hyperglycaemia and improves insulin sensitivity [14, 15] . Furthermore, adiponectin-deficient mice develop diet-induced IR on a high-fat/high-sucrose diet [16] . In humans, plasma levels of adiponectin are significantly lower in insulin-resistant states including type 2 diabetes [17] and can be increased upon administration of the insulin-sensitizing agents by Thiazolidinedione or TZDs, also known as glitazones, that act by activating PPARs (peroxisome proliferator-activated receptors) [18] [19] [20] [21] . We found that serum adiponectin levels of healthy control group were conspicuously higher than obese and nonobese diabetics. Although adiponectin levels of diabetic non-obese group were higher than the obese group but this elevation was not statistically significant. So that, there was no differences between diabetics groups. Although adiponectin was negatively correlated with BMI as a convenient calculator of obesity, it is apparent from our study of obese and nonobese diabetic individuals adiponectin levels looks like more tightly linked with insulin resistance when we look at the correlation table.
Altınova et al. [22] resulted that circulating adiponectin is associated with insulin resistance independent from BMI in overweight subjects. Decreased adiponectin levels in type 2 diabetes may be one of the reasons to cause insulin resistance [23] . The HOMA model is used to quantify insulin resistance and beta-cell function from fasting plasma insulin and glucose concentrations [24] . The relationship between glucose and insulin in the basal state reflects the balance between hepatic glucose output and insulin secretion, which is regularized by a feedback circuit between the liver and β-cells. Numerous studies [25] showed that adiponectin improved insulin sensitivity mainly by increasing fatty acids oxidation and inhibition of hepatic glucose production by stimulatory effects of adiponectin on signalling pathways for 5′ adenosine monophos- Values are expressed as means ± SD or medians ( 25th -75th percentiles), BMI, Body Mass Index, HbA1c, haemoglobin A1c, HOMA-IR, homeostatic model assessment index, ns; not significant, a; obese versus control, b; non-obese versus control, c; obese versus non-obese Visfatin is expressed in many cells and tissues, and was previously recognized as a Pre-B Cell Colony Enhancing Factor (PBEF). In recent times, visfatin was described to be a highly expressed protein with insulin-mimetic functions, and was predominantly found in visceral adipose tissue [31] . There are numerous incompatibilities among the different studies of visfatin, and the role of this adipokine in obesity and insulin resistance is not clear.
In the current study, we found that serum visfatin concentrations were significantly higher in the diabetic obese compared with the control group and diabetic groups showed a significant positive correlation with measures of obesity with BMI in opposition to adiponectin. In accordance with our results, Berndt et. al. [32] and Varma et. al. [33] found a significant positive correlation between visfatin levels and BMI. In our results, diabetic patients showed a significant positive correlation between serum visfatin concentrations and HOMA-IR; in accordance with the results of Sandeep et al. [34] , who found a strong correlation between serum visfatin and HOMA. We showed that an elevated visfatin level in patients with T2DM, and suggests that this phenomenon is not prejudiced by the extent of overweight/obesity. In normal participants, plasma visfatin is increased with elevated blood glucose by the glucose clamp test [35] . On the basis of this disclosure, our results may support the idea that elevated visfatin in patients with T2DM may be a consequence of the hyperglycaemia conditions. The present study seems to have some limitations. First, the sample size was small to represent all people with T2DM. Second, we estimated insulin resistance using HOMA-IR model for which some limitations were reported [24] . In this study, our analyses are based on single measurements of blood visfatin and adiponectin, which may not reflect the relationship over time. It would be interesting to measure serial changes of visfatin and adiponectin levels in obese, insulin resistant phate-activated protein kinase and peroxisome proliferator-activated receptor α. In our study, adiponectin levels that negatively correlated with HOMA rather than adiposity in which that high HOMA-IR value indicates low insulin sensitivity (insulin resistance) may be an extremely important for type 2 diabetes which is an indicator predicting development of insulin resistance in terms of early diagnosis can give important insight.
The association between adiponectin levels and the 6-year risk of type 2 diabetes in a population of 2500 older white men and women were investigated by The Hoorn Study [26] and this study showed that a lower adiponectin level associated with a higher risk of type 2 diabetes. In the British Regional Heart Study (BRHS) showed that, men with adiponectin concentrations in the top tertile (vs. the bottom tertile) had a 60% lower risk of incident type 2 diabetes after 5 years [27] . These results are shown an inverse correlation between the adiponectin concentration and the duration of diabetes and this correlation is also confirmed in our results. We have observed that adiponectin may have a central role in the pathogenesis of T2DM and low adiponectin concentration may be a candidate messenger of future development of T2DM in subjects with obesity compared to healthy.
These effects may be in part mediated by the level of expression of both the AdipoR1 and AdipoR2 receptors [28] and the distribution of the HMW (High Molecular Weight isomer of Adiponectin) and LMW (Low Molecular Weight isomer of Adiponectin) isoforms of adiponectin may play a role in insulin sensitivity [29] . The negative correlation with BMI may be a good indicator about obesity related insulin resistance in T2DM, but in obese and non-obese type 2 diabetic groups, failure to establish the their inverse relationship may be attributed partially by other hormones such as catecholamines or androgen, by proinflammatory cytokines such as TNF-α, by medications, by insulin levels, or possibly by changes in clearance of adiponectin [30] . subjects clarify further, the roles of visfatin and adiponectin in the pathogenesis of T2DM. On the other hand variation levels that related to intra-and inter-individuals have not been estimated. Due to unknown biological variation, evaluation of the difference has not been considered. Therefore, in order to be able to say different, the need for the determination of the existence of this concept should not be ignored.
In conclusion that increased body weight is tightly associated with insulin resistance and Type 2 Diabetes Mellitus. The roles of various adipokines as connectors between obesity and diabetes mellitus have been better elucidated in recent times. On the basis of this study finding, adiponectin and visfatin levels can be associated with insulin sensitivity at obese diabetic patients compared to healthy control. Future prospective studies with greater numbers of patient are recommended to establish a direct relationship between serum adiponectin and visfatin concentrations.
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